Ischemic Stroke Clinical Trial
Official title:
Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke
Verified date | June 2019 |
Source | Northwell Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the incidence of paroxysmal atrial fibrillation (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial fibrillation.
Status | Completed |
Enrollment | 53 |
Est. completion date | September 28, 2017 |
Est. primary completion date | September 28, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 41 Years and older |
Eligibility |
Inclusion Criteria: - Patients with a recent ischemic stroke or transient ischemic attack (TIA) with brain infarction on brain imaging. - No history of atrial fibrillation or finding of atrial fibrillation on standard inpatient monitoring (electrocardiogram, telemetry, 24-hour Holter monitor) - Have a presumed stroke etiology: Lacunar or small vessel thrombosis, extra-cranial or intracranial atherosclerotic stenosis or dissection, arteriopathy or vasculitis, hypercoagulable state, aortic arch plaque with or without mobile elements, or evidence of a low-risk cardiac source (e.g., patent foramen ovale with or without atrial septal aneurysm and with or without evidence of venous thromboembolic source). - Have virtual CHADS2 score =3 or - Have 2 or more of the following co-morbidities: obstructive sleep apnea, coronary artery disease, (Chronic Pulmonary Obstructive Disease (COPD), hyperthyroidism, Body Mass Index> 30, prior myocardial infarction, prolonged PR interval (>175 ms) or renal impairment (GFR 30-60). - Patient or legally authorized representative who is willing to sign written consent form. - Patient is =40 years old (patients younger than 40 years old have a very low likelihood of having atrial fibrillation and are therefore excluded from the study). - Patient can have the device implanted within 7 days of the incident ischemic event Exclusion Criteria: - Documented history of AF or atrial flutter. - Evidence of a high-risk cardiac source of embolism (Left Ventricular or Left Atrial thrombus or "smoke," emboligenic valvular lesion or tumor) - Untreated hyperthyroidism. - Myocardial infarction or coronary bypass grafting within 1 month prior to the stroke/TIA. - Valvular disease requiring immediate surgical intervention. - Permanent indication for anticoagulation at enrollment. - Permanent oral anticoagulation contraindication. - Already included in another clinical trial that will affect the objectives of this study. - Life expectancy is less than 1 year. - Pregnancy. Urine or serum pregnancy test is required for women of child bearing potential to exclude pregnancy. - Patient is indicated for implant with a pacemaker, implantable cardioverter-defibrillator, CRT device, or an implantable hemodynamic monitoring system - Patient is not fit, or is unable or unwilling to follow the required procedures of the Clinical Investigation Plan. - Cryptogenic Stroke: A stroke/TIA will be considered cryptogenic if no cause is determined despite extensive inpatient workup according to the standard diagnostic protocol at North Shore University Hospital. |
Country | Name | City | State |
---|---|---|---|
United States | North Shore University Hospital | Manhasset | New York |
United States | Long Island Jewish Medical Center | New Hyde Park | New York |
Lead Sponsor | Collaborator |
---|---|
Northwell Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients | The incidence of paroxysmal atrial fibrillation (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial fibrillation. | 1 year | |
Secondary | Patients Who Are Diagnosed With AF Who Are Changed to Anticoagulant Therapy. | Percentage of patients who are diagnosed with AF who are changed to anticoagulant therapy. | 1 year | |
Secondary | Duration of AF Episodes. | Duration of AF episodes (mean and range). | 1 year | |
Secondary | Percentage of Asymptomatic AF | Percentage of asymptomatic AF episodes. | 1 year | |
Secondary | Incidence of Recurrent Stroke | Incidence of recurrent ischemic stroke. | 1 year | |
Secondary | Number of Patients That Had Multiple AF Episodes | Number of patients that had multiple AF episodes. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT02924168 -
Radial Shock Waves for Functional Disability in Stroke
|
N/A |